{"blog": [], "keywords": [{"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Pfizer Inc", "name": "organizations", "rank": "3", "is_major": "N"}, {"value": "Read, Ian C", "name": "persons", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/09/27/business/dealbook/pfizer-remains-whole-but-the-option-to-split-could-return.html", "document_type": "article", "byline": {"person": [{"lastname": "CYRAN", "firstname": "Robert", "role": "reported", "organization": "", "rank": 1}], "original": "By ROBERT CYRAN"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbWide.jpg", "legacy": {"wide": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg", "legacy": {"xlarge": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "396", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up.", "pub_date": "2016-09-27T04:00:00+0000", "news_desk": "Business", "headline": {"kicker": "Breakingviews", "main": "Pfizer Remains Whole, but the Option to Split Could Return", "content_kicker": "Breakingviews"}, "print_page": null, "snippet": "Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up....", "_id": "57e95e8895d0e021d7988700", "slideshow_credits": null, "abstract": null}